Skip to content
Search

Latest Stories

Drug shortages are forcing patients to visit multiple pharmacies or go back to GP for an alternative

There has been extensive national media coverage today (August 11) on how medicine or drug shortages have forced patients to visit multiple pharmacies to get their prescriptions filled or return to their GP to be prescribed alternative drugs.

These media reports have been based on a survey involving more than 1,500 pharmacists in the UK, in which over a half of those polled said that their patients' health had been put at risk in the last six months.


In response to a query from Pharmacy Business, the Department of Health and Social Care (DHSC) said it monitors the medicines supply chain closely to prevent any shortages and acts swiftly when any issue arises.

A DHSC spokesperson told Pharmacy Business: "We take patient safety extremely seriously and we routinely share information about medicine supply issues directly with the NHS so they can put plans in place to reduce the risk of any shortage impacting patients, including offering alternative medication.

“We have well-established procedures to deal with medicine shortages and work closely with industry, the NHS and others to prevent shortages and resolve any issues as soon as possible."

Pharmacy Business was informed of the way in which the department works closely with the MHRA, the pharmaceutical industry, the NHS and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.

It routinely shares information about medicine supply issues directly with the NHS so it can put management plans in place to mitigate the risk of the shortage impacting patients.

Asked why shortages happen and what measures the DHSC has put in place to mitigate the risk to patients, the DHSC clarified that production of medicines is complex and highly regulated, and that materials and processes needed to meet rigorous safety and quality standards.

The department admitted that occasionally the NHS does experience temporary shortages of specific medicines and that these can occur for a number of reasons: due to manufacturing difficulties, regulatory problems and problems with the supply of raw materials, or from issues which are related to the distribution of the product.

A children's hospital pharmacist is said to have raised concerns about variable supply of nutritional products and explained how it was putting patients at risk. "We had to ration it, and this has potentially put patients at risk of vitamin deficiencies," she said.

Another hospital pharmacist spoke of drugs used in end-of-life care being unavailable: "There was no alternative for one patient who had to deal with an additional symptom in his last days of life due to lack of available treatment."

Although a fifth of those polled did not think patients had been endangered and a quarter did not know, short supply of medicines have been headlined in the recent months. Shortage of hormone replacement therapy (HRT) products used by millions of women going through menopause sparked an outcry earlier this year, which led to ministers launching an HRT supply task force and consequently appointing an HRT tsar to work with manufacturers to improve access.

Speaking to The Daily Express newspaper, menopause mentor Elizabeth Carr-Ellis said: “It’s three years since I first talked about HRT shortages. In that time, I’ve paid for prescriptions that haven’t been filled, had to have my medication changed because it wasn’t in stock and generally just been worried every time I have to ask for more as I’m never sure if I’ll get it.

“Women contact me all the time to say they can’t get their HRT, adding huge stress onto a time that’s often already stressing them out.”

Since June, the department has issued a number of "medicine supply notifications", highlighting shortages. Some of these include: pain relief drugs used in childbirth; mouth ulcer medication; migraine treatment; an antihistamine; a drug used by prostate cancer and endomitosis patients; an antipsychotic drug used among bipolar disorder and schizophrenia patients; a type of inhaler and a certain brand of insulin.

Some of medicines that have suffered severe supply issues, such as - Combisal (Fluticasone 125microgram Salmeterol 25microgram); Atorvastatin (Lipitor): 10mg; Fluoxetine 10mg tablets; Oestrogel Pump-Pack 0.06 per cent gel and paracetamol suppositories 120mg - have all been issued Serious Shortage Protocols.

In a news report on Aug 7, just days ahead of the publication of the current survey, Express said the UK was facing a critical shortage of life-saving drugs including antibiotics, insulin and antidepressants. It stressed that "the impending crisis means that many people could now be turning to risky online sellers for vital medications".

"The problems are being caused by a shortage of raw ingredients used to manufacture medicines. These are often supplied by countries in the Far East [particularly China which is a major supplier of active pharmaceutical ingredients]. There are also rising costs set by pharmaceutical manufacturers and wholesalers," the paper wrote.

The newspaper quoted Dr Leyla Hannbeck, CEO of the Association of Independent Multiple Pharmacies, as saying: "We are trying hard to ensure patients get their medicines and we don't want people to worry but it's an absolute nightmare in the already overstretched pharmacies that are battling big challenges with workforce pressures."

Dr Hannbeck added: "They get desperate and get their hands on medicines from the internet, where it is not safe. We don't know why the government is not responding swiftly enough to tackle the issue."

In a recent Pharmacy Pressures Survey, the Pharmaceutical Services Negotiating Committee found that 83 of pharmacies polled reported of a significant increase in medicine supply issues in the past year.

The National Pharmacy Association has always maintained how pharmacists went to great lengths to source medicines for their patients but their hands were tied.

A spokesperson said: “Delays are always inconvenient and frustrating, and they can also sometimes be a risk to the patient’s health.

"Pharmacists should be given greater flexibility to take decisions at the point of care to manage medical supplies.”

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less